MARK BASIRATMAND: Open Payments
NPI 1154836153 · BROOKLYN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,318 in 35 payments from 9 companies in 2025. Trend: 2023 $709 · 2024 $1,751 · 2025 $1,318
Food & beverage: $1,318
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 12 | $342 |
| Novo Nordisk Inc | 11 | $329 |
| Ardelyx, Inc. | 4 | $203 |
| Madrigal Pharmaceuticals | 1 | $150 |
| ABBVIE INC. | 1 | $143 |
| Lilly USA, LLC | 2 | $56 |
| Intra-Sana Laboratories | 2 | $56 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
Products named: REPATHA, Ozempic, IBSRELA, REZDIFFRA, CREON, Rybelsus, RELTONE 200 MG, OTEZLA.
Industry payments across NY — which companies pay providers there.
